KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Neogenomics (NEO) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Neogenomics (NEO) over the last 16 years, with Q4 2025 value amounting to $209.1 million.

  • Neogenomics' Accumulated Depreciation & Amortization rose 1003.58% to $209.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $209.1 million, marking a year-over-year increase of 1003.58%. This contributed to the annual value of $209.1 million for FY2025, which is 1003.58% up from last year.
  • Per Neogenomics' latest filing, its Accumulated Depreciation & Amortization stood at $209.1 million for Q4 2025, which was up 1003.58% from $190.0 million recorded in Q4 2024.
  • Neogenomics' Accumulated Depreciation & Amortization's 5-year high stood at $209.1 million during Q4 2025, with a 5-year trough of $110.0 million in Q4 2021.
  • In the last 5 years, Neogenomics' Accumulated Depreciation & Amortization had a median value of $158.2 million in 2023 and averaged $159.8 million.
  • In the last 5 years, Neogenomics' Accumulated Depreciation & Amortization surged by 32445.95% in 2021 and then surged by 1003.58% in 2025.
  • Quarter analysis of 5 years shows Neogenomics' Accumulated Depreciation & Amortization stood at $110.0 million in 2021, then grew by 19.99% to $131.9 million in 2022, then grew by 19.92% to $158.2 million in 2023, then rose by 20.09% to $190.0 million in 2024, then rose by 10.04% to $209.1 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $209.1 million for Q4 2025, versus $190.0 million for Q4 2024 and $158.2 million for Q4 2023.